{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T17:25:36Z","timestamp":1787505936230,"version":"build-2736575974"},"reference-count":63,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004385","name":"Ghent University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004385","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004727","name":"Vlaams Instituut voor Biotechnologie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004727","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacological Research"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.phrs.2025.107709","type":"journal-article","created":{"date-parts":[[2025,3,23]],"date-time":"2025-03-23T18:58:44Z","timestamp":1742756324000},"page":"107709","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["CCR1 inhibition sensitizes multiple myeloma cells to glucocorticoid therapy"],"prefix":"10.1016","volume":"215","author":[{"given":"Bert","family":"Luyckx","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maaike","family":"Van Trimpont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fien","family":"Declerck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleni","family":"Staessens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annick","family":"Verhee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"T\u2019Sas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sven","family":"Eyckerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fritz","family":"Offner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter","family":"Van Vlierberghe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Goossens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorien","family":"Clarisse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolien","family":"De Bosscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2024","key":"10.1016\/j.phrs.2025.107709_bib1","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/ajh.26590","article-title":"Update on diagnosis, risk-stratification, and management","volume":"97","author":"Rajkumar","year":"2022","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.phrs.2025.107709_bib2","doi-asserted-by":"crossref","first-page":"55809","DOI":"10.1074\/jbc.M411767200","article-title":"Inhibition of glucocorticoid-induced apoptosis by targeting the major splice variants of BIM mRNA with small interfering RNA and short hairpin RNA","volume":"279","author":"Abrams","year":"2004","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2025.107709_bib3","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/s00262-013-1477-8","article-title":"Non-genomic events determining the sensitivity of hemopoietic malignancies to glucocorticoid-induced apoptosis","volume":"63","author":"Kfir-Erenfeld","year":"2014","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.phrs.2025.107709_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2020.188430","article-title":"Latest perspectives on glucocorticoid-induced apoptosis and resistance in lymphoid malignancies","volume":"1874","author":"Clarisse","year":"2020","journal-title":"Biochim. Biophys. Acta - Rev. Cancer"},{"key":"10.1016\/j.phrs.2025.107709_bib5","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1080\/10428194.2022.2136950","article-title":"From mechanism to resistance\u2013changes in the use of dexamethasone in the treatment of multiple myeloma","volume":"64","author":"Rosenberg","year":"2023","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.phrs.2025.107709_bib6","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-022-00695-5","article-title":"Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: consensus recommendations of the NCI Multiple Myeloma Steering Committee","volume":"12","author":"Kumar","year":"2022","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.phrs.2025.107709_bib7","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1182\/blood.V80.4.887.887","article-title":"Primary dexamethasone treatment of multiple myeloma","volume":"80","author":"Alexanian","year":"1992","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2025.107709_bib8","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1182\/blood-2014-11-568881","article-title":"Pathogenesis beyond the cancer clone(s) in multiple myeloma","volume":"125","author":"Bianchi","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2025.107709_bib9","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-47793-5","article-title":"Bone marrow stromal cells induce chromatin remodeling in multiple myeloma cells leading to transcriptional changes","volume":"15","author":"Binder","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.phrs.2025.107709_bib10","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-017-0037-4","article-title":"Pathogenesis of bone disease in multiple myeloma: from bench to bedside","volume":"8","author":"Terpos","year":"2018","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.phrs.2025.107709_bib11","doi-asserted-by":"crossref","first-page":"5991","DOI":"10.1038\/sj.onc.1204833","article-title":"Biologic sequelae of interleukin-6 induced PI3-K\/Akt signaling in multiple myeloma","volume":"20","author":"Hideshima","year":"2001","journal-title":"Oncogene"},{"key":"10.1016\/j.phrs.2025.107709_bib12","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-48818-9","article-title":"Glucocorticoids paradoxically promote steroid resistance in B cell acute lymphoblastic leukemia through CXCR4\/PLC signaling","volume":"15","author":"Abdoul-Azize","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.phrs.2025.107709_bib13","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1182\/blood.V84.9.3063.3063","article-title":"Interleukin-6 prevents dexamethasone-induced myeloma cell death","volume":"84","author":"Hardin","year":"1994","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2025.107709_bib14","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/0092-8674(93)90118-A","article-title":"Molecular cloning, functional expression, and signaling characteristics of a C-C chemokine receptor","volume":"72","author":"Neote","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2025.107709_bib15","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s10585-006-9038-6","article-title":"Role of CCR1 and CCR5 in homing and growth of multiple myeloma and in the development of osteolytic lesions: a study in the 5TMM model","volume":"23","author":"Menu","year":"2006","journal-title":"Clin. Exp. Metastas-.-."},{"key":"10.1016\/j.phrs.2025.107709_bib16","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-022-31810-6","article-title":"The surfaceome of multiple myeloma cells suggests potential immunotherapeutic strategies and protein markers of drug resistance","volume":"13","author":"Ferguson","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.phrs.2025.107709_bib17","doi-asserted-by":"crossref","first-page":"3568","DOI":"10.1182\/blood-2002-08-2383","article-title":"Macrophage inflammatory protein 1-alpha (MIP-1\u03b1) triggers migration and signaling cascades mediating survival and proliferation in multiple myeloma (MM) cells","volume":"101","author":"Lentzsch","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2025.107709_bib18","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1046\/j.1365-2141.2003.04561.x","article-title":"Serum levels of macrophage inflammatory protein-1 alpha (MIP-1\u03b1) correlate with the extent of bone disease and survival in patients with multiple myeloma","volume":"123","author":"Terpos","year":"2003","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.phrs.2025.107709_bib19","doi-asserted-by":"crossref","first-page":"4258","DOI":"10.1002\/jcp.26245","article-title":"The MIP-1\u03b1 autocrine loop contributes to decreased sensitivity to anticancer drugs","volume":"233","author":"Tsubaki","year":"2018","journal-title":"J. Cell. Physiol."},{"key":"10.1016\/j.phrs.2025.107709_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2024.107469","article-title":"Expression of the chemokine receptor CCR1 decreases sensitivity to bortezomib in multiple myeloma cell lines","volume":"139","author":"Zeissig","year":"2024","journal-title":"Leuk. Res."},{"key":"10.1016\/j.phrs.2025.107709_bib21","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1182\/blood-2011-10-384784","article-title":"CCR1 blockade reduces tumor burden and osteolysis in vivo in a mouse model of myeloma bone disease","volume":"120","author":"Dairaghi","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2025.107709_bib22","first-page":"316","article-title":"Expression of the chemokine receptor CCR1 promotes the dissemination of multiple myeloma plasma cells in vivo","volume":"106","author":"Zeissig","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.phrs.2025.107709_bib23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fendo.2022.846310","article-title":"Targeting Chemokine Receptor CCR1 as a Potential Therapeutic Approach for Multiple Myeloma","volume":"13","author":"Gilchrist","year":"2022","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.phrs.2025.107709_bib24","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1038\/sj.onc.1205205","article-title":"Identification of genes regulated by Dexamethasone in multiple myeloma cells using oligonucleotide arrays","volume":"21","author":"Chauhan","year":"2002","journal-title":"Oncogene"},{"key":"10.1016\/j.phrs.2025.107709_bib25","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s00277-018-3465-8","article-title":"Glucocorticoids in multiple myeloma: past, present, and future","volume":"98","author":"Burwick","year":"2019","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.phrs.2025.107709_bib26","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1182\/blood-2010-02-268862","article-title":"Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma","volume":"116","author":"Richardson","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2025.107709_bib27","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1182\/blood-2017-08-797886","article-title":"Safety and efficacy of selinexor in relapsed or refractory multiple myeloma and Waldenstrom macroglobulinemia","volume":"131","author":"Chen","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2025.107709_bib28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00018-023-04900-x","article-title":"Crosstalk between glucocorticoid and mineralocorticoid receptors boosts glucocorticoid-induced killing of multiple myeloma cells","volume":"80","author":"Clarisse","year":"2023","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.phrs.2025.107709_bib29","article-title":"Leveraging a self-cleaving peptide for tailored control in proximity labeling proteomics","volume":"4","author":"Delhaye","year":"2024","journal-title":"Cell Rep. Methods"},{"key":"10.1016\/j.phrs.2025.107709_bib30","doi-asserted-by":"crossref","first-page":"19000","DOI":"10.1074\/jbc.M001222200","article-title":"Identification and characterization of a potent, selective, and orally active antagonist of the CC chemokine receptor-1","volume":"275","author":"Liang","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2025.107709_bib31","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1182\/blood-2003-02-0380","article-title":"Soluble receptor activator of nuclear factor \u03baB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index","volume":"102","author":"Terpos","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2025.107709_bib32","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.ymthe.2019.01.012","article-title":"miR-221\/222-mediated inhibition of autophagy promotes dexamethasone resistance in multiple myeloma","volume":"27","author":"Xu","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/j.phrs.2025.107709_bib33","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.cell.2010.01.028","article-title":"Methods in mammalian autophagy research","volume":"140","author":"Mizushima","year":"2010","journal-title":"Cell"},{"key":"10.1016\/j.phrs.2025.107709_bib34","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1111\/j.1365-2141.2004.04949.x","article-title":"Characterisation of Mcl-1 cleavage during apoptosis of haematopoietic cells","volume":"125","author":"Clohessy","year":"2004","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.phrs.2025.107709_bib35","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1182\/blood.V100.1.194","article-title":"Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-xL is an essential survival protein of human myeloma cells","volume":"100","author":"Derenne","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2025.107709_bib36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fonc.2018.00533","article-title":"Role and regulation of pro-survival BCL-2 proteins in multiple myeloma","volume":"8","author":"Slomp","year":"2018","journal-title":"Front. Oncol."},{"key":"10.1016\/j.phrs.2025.107709_bib37","doi-asserted-by":"crossref","first-page":"5452","DOI":"10.1158\/0008-5472.CAN-17-0115","article-title":"HIF-2\u03b1 promotes dissemination of plasma cells in multiple myeloma by regulating CXCL12\/CXCR4 and CCR1","volume":"77","author":"Vandyke","year":"2017","journal-title":"Cancer Res"},{"key":"10.1016\/j.phrs.2025.107709_bib38","doi-asserted-by":"crossref","first-page":"32194","DOI":"10.1074\/jbc.M113.503797","article-title":"The chemokine receptor CCR1 is constitutively active, which leads to G protein-independent, \u03b2-arrestin-mediated internalization","volume":"288","author":"Gilliland","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2025.107709_bib39","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1038\/leu.2011.43","article-title":"A novel role for CCL3 (MIP-1\u03b1) in myeloma-induced bone disease via osteocalcin downregulation and inhibition of osteoblast function","volume":"25","author":"Vallet","year":"2011","journal-title":"Leukemia"},{"key":"10.1016\/j.phrs.2025.107709_bib40","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1038\/onc.2016.515","article-title":"Macrophages confer survival signals via CCR1-dependent translational MCL-1 induction in chronic lymphocytic leukemia","volume":"36","author":"Van Attekum","year":"2017","journal-title":"Oncogene"},{"key":"10.1016\/j.phrs.2025.107709_bib41","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1172\/JCI0214040","article-title":"A chemokine receptor CCR-1 antagonist reduces renal fibrosis after unilateral ureter ligation","volume":"109","author":"Anders","year":"2002","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.phrs.2025.107709_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.envpol.2021.118050","article-title":"Acute and subacute oral toxicity of propylene glycol enantiomers in mice and the underlying nephrotoxic mechanism","volume":"290","author":"Zhou","year":"2021","journal-title":"Environ. Pollut."},{"key":"10.1016\/j.phrs.2025.107709_bib43","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.canlet.2020.05.028","article-title":"Disruption of CCR1-mediated myeloid cell accumulation suppresses colorectal cancer progression in mice","volume":"487","author":"Kiyasu","year":"2020","journal-title":"Cancer Lett."},{"key":"10.1016\/j.phrs.2025.107709_bib44","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1038\/s41416-024-02710-x","article-title":"Synergistic antitumor activity by dual blockade of CCR1 and CXCR2 expressed on myeloid cells within the tumor microenvironment","volume":"131","author":"Masui","year":"2024","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.phrs.2025.107709_bib45","doi-asserted-by":"crossref","first-page":"3572","DOI":"10.1002\/art.24978","article-title":"MLN3897 plus methotrexate in patients with rheumatoid arthritis: safety, efficacy, pharmacokinetics, and pharmacodynamics of an oral CCR1 antagonist in a phase IIa, double-blind, placebo-controlled, randomized, proof-of-concept study","volume":"60","author":"Vergunst","year":"2009","journal-title":"Arthritis Rheum."},{"key":"10.1016\/j.phrs.2025.107709_bib46","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41423-023-01032-x","article-title":"New genetic and epigenetic insights into the chemokine system: the latest discoveries aiding progression toward precision medicine","volume":"20","author":"Xu","year":"2023","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.phrs.2025.107709_bib47","first-page":"1","article-title":"Co-evolution of tumor and immune cells during progression of multiple myeloma","volume":"12","author":"Liu","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.phrs.2025.107709_bib48","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/cddis.2013.348","article-title":"Dexamethasone shifts bone marrow stromal cells from osteoblasts to adipocytes by C\/EBP\u03b1lpha promoter methylation","volume":"4","author":"Li","year":"2013","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.phrs.2025.107709_bib49","doi-asserted-by":"crossref","first-page":"3325","DOI":"10.1182\/blood-2012-10-435750","article-title":"Optimal use of bisphosphonates in patients with multiple myeloma","volume":"121","author":"Terpos","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2025.107709_bib50","doi-asserted-by":"crossref","first-page":"e9","DOI":"10.1182\/blood-2012-03-414920","article-title":"Reconstructing the human hematopoietic niche in immunodeficient mice: opportunities for studying primary multiple myeloma","volume":"120","author":"Groen","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.phrs.2025.107709_bib51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fgene.2021.640954","article-title":"Animal models of multiple myeloma bone disease","volume":"12","author":"Mehdi","year":"2021","journal-title":"Front. Genet"},{"key":"10.1016\/j.phrs.2025.107709_bib52","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/ni.2524","article-title":"Plasma cells require autophagy for sustainable immunoglobulin production","volume":"14","author":"Pengo","year":"2013","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.phrs.2025.107709_bib53","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1016\/j.tranon.2018.08.014","article-title":"Autophagy: a new mechanism of prosurvival and drug resistance in multiple myeloma","volume":"11","author":"Desantis","year":"2018","journal-title":"Transl. Oncol."},{"key":"10.1016\/j.phrs.2025.107709_bib54","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-023-05786-0","article-title":"Cathepsin B in programmed cell death machinery: mechanisms of execution and regulatory pathways","volume":"14","author":"Xie","year":"2023","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.phrs.2025.107709_bib55","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15020445","article-title":"Dexamethasone-induced fatty acid oxidation and autophagy\/mitophagy are essential for T-ALL glucocorticoid resistance","volume":"15","author":"Olivas-Aguirre","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.phrs.2025.107709_bib56","doi-asserted-by":"crossref","first-page":"26816","DOI":"10.1074\/jbc.M109.000646","article-title":"Targeting glucose consumption and autophagy in myeloma with the novel nucleoside analogue 8-aminoadenosine","volume":"284","author":"Shanmugam","year":"2009","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2025.107709_bib57","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1074\/jbc.M109.065813","article-title":"Cathepsin B-mediated autophagy flux facilitates the anthrax toxin receptor 2-mediated delivery of anthrax lethal factor into the cytoplasm","volume":"285","author":"Ha","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.phrs.2025.107709_bib58","doi-asserted-by":"crossref","first-page":"70845","DOI":"10.18632\/oncotarget.12226","article-title":"Hydroxychloroquine potentiates carfilzomib toxicity towards myeloma cells","volume":"7","author":"Baranowska","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.phrs.2025.107709_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105582","article-title":"Chloroquine and hydroxychloroquine in antitumor therapies based on autophagy-related mechanisms","volume":"168","author":"Ferreira","year":"2021","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.phrs.2025.107709_bib60","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1097\/01.HS9.0000846668.54265.08","article-title":"P950: combined proteasome and autophagy inhibition in relapsed\/refractory multiple myeloma \u2013 a phase I trial of hydroxychloroquine, carfilzomib and dexamethasone","volume":"6","author":"Sl\u00f8rdahl","year":"2022","journal-title":"HemaSphere"},{"key":"10.1016\/j.phrs.2025.107709_bib61","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1158\/0008-5472.CAN-11-2781","article-title":"Identification of molecular vulnerabilities in human multiple myeloma cells by RNA interference lethality screening of the druggable genome","volume":"72","author":"Tiedemann","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.phrs.2025.107709_bib62","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1182\/bloodadvances.2020003624","article-title":"Direct P70S6K1 inhibition to replace dexamethasone in synergistic combination with MCL-1 inhibition in multiple myeloma","volume":"5","author":"Spaan","year":"2021","journal-title":"Blood Adv."},{"key":"10.1016\/j.phrs.2025.107709_bib63","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/fonc.2023.1226289","article-title":"Targeting MCL-1 protein to treat cancer: opportunities and challenges","volume":"13","author":"Tantawy","year":"2023","journal-title":"Front. Oncol."}],"container-title":["Pharmacological Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661825001343?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1043661825001343?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T14:45:56Z","timestamp":1762353956000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1043661825001343"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":63,"alternative-id":["S1043661825001343"],"URL":"https:\/\/doi.org\/10.1016\/j.phrs.2025.107709","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.12.05.626954","asserted-by":"object"}]},"ISSN":["1043-6618"],"issn-type":[{"value":"1043-6618","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CCR1 inhibition sensitizes multiple myeloma cells to glucocorticoid therapy","name":"articletitle","label":"Article Title"},{"value":"Pharmacological Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.phrs.2025.107709","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"107709"}}